Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections

International Journal of Antimicrobial Agents

Volumn 18, Issue 3, 2001, Pages 199-209

  Lode, H ^a  

^a Pneumologie I   (Germany)

Author keywords

Ampicillin; Respiratory tract infection; Sulbactam; Sultamicillin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFOTAXIME; CEFOXITIN; CEFUROXIME; MEZLOCILLIN; SULBACTAM; SULTAMICILLIN; TIMENTIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIMICROBIAL ACTIVITY; CHILD; CHRONIC BRONCHITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; DERMATITIS; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; HEADACHE; HUMAN; IMPETIGO BULLOSA; LIVER DYSFUNCTION; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OTITIS MEDIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SEDATION; TASTE DISORDER; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA DISCHARGE;

EID: 0034781311     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00387-9     Document Type: Article

References (67)

1. Penicillins. A current review of their clinical pharmacology and therapeutic use
2. Epidemiology of resistance to antimicrobial drugs in the major respiratory pathogens circulating in Europe
3. The beta-lactamase problem: new therapeutic options
4. Community-acquired pneumonia guidelines-an international comparison: a view from Europe
5. Beta-lactamases and beta-lactamase inhibitors
6. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens-findings of the Alexander Project 1992-1996
7. Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use
8. Worldwide clinical experience with sultamicillin
9. Low-dose sultamicillin oral suspension in the treatment of mild-to-moderate paediatric infections in Turkey
10. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin
11. A functional classification scheme for beta-lactamases and its correlation with molecular structure
12. Beta-lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone
13. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use
14. In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations
15. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic Gram-positive and Gram-negative bacteria
16. Effect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria
17. The pharmacokinetics of sultamicillin
18. Pharmacokinetics of sulbactam/ampicillin in humans: a review
19. Oral bioavailability of ampicillin and amoxycillin alone and bound in fixed proportions to sulbactam and clavulanic acid
20. An open non-comparative study of the efficacy and tolerability of sultamicillin in the therapy of respiratory infections in childhood
21. An open multicentre study to compare the efficacy and safety of sultamicillin with that of cefuroxime axetil in acute ear nose and throat infections in adults
22. Sultamicillin versus amoxicillin in the treatment of tonsillitis and pharyngitis: a European multicenter study
23. Sulbactam/ampicillin in the treatment of otitis and sinusitis
24. An open non-comparative pilot study of the safety and efficacy of oral sultamicillin in the treatment of mild to moderate upper respiratory tract infections in children
25. Sultamicillin (ampicillin-sulbactam) in the treatment of acute otitis media in children
26. Sultamicillin (sulbactam/ampicillin) versus amoxycillin in the treatment of acute otitis media in children
27. An open comparative study of the efficacy and safety of sultamicillin versus cefaclor in the treatment of acute otitis media in children
28. Comparative study of sultamicillin and amoxicillin-clavulanate: treatment of acute otitis media
29. A non-comparative study of parenteral ampicillin and sulbactam in intra-thoracic and intra-abdominal infections
30. A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract
31. A comparison of ampicillin/sulbactam versus cefotaxime in the therapy of lower respiratory tract infections in hospitalized patients
32. Intravenous ampicillin/sulbactam versus cefuroxime axetil in the treatment of patients hospitalized with community-acquired lower respiratory tract infections
33. Which antibiotic is better for the treatment of infections of the lower respiratory tract?
34. Comparison of sulbactam/ampicillin and cefuroxime in infections of the lower respiratory tract: results of a prospective, randomized and comparative study
35. A comparison of ampicillin/sulbactam versus cefuroxime in the therapy of lower respiratory tract infections
36. Treatment of LRTIs: two antimicrobials compared
37. A non-comparative study of the safety and efficacy of parenteral sulbactam/ampicillin followed by oral sultamicillin for the treatment of lower respiratory tract infections
38. Treatment of lower respiratory tract infections with sultamicillin
39. Can the choice of antibiotics for therapy of acute otitis media be logical?
40. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992
41. Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections
42. Meta-analysis of the efficacy and safety of ampicillin/sulbactam in the treatment of patients with bacterial infections of the lower respiratory tract
43. A comparison of ampicillin/sulbactam with cefoxitin in the treatment of lower respiratory tract infections of bacterial etiology
44. Ampicillin/sulbactam compared with cefotaxime in the treatment of lower respiratory tract infections of bacterial etiology
45. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia
46. A comparison of ampicillin/sulbactam with cefamandole in the treatment of bacterial pneumonia in the elderly
47. Effectiveness of sulbactam/ampicillin in the treatment of lobar pneumonia
48. Efficacy of sulbactam-ampicillin combination in the treatment of severe community-acquired pneumonia
49. Sulbactam-ampicillin monotherapy in the ambulatory treatment of pneumonia. Results of mono-administration
50. Clinical efficacy of sulbactam/ampicillin in comparison with cefotiam in the treatment of elderly patients with pneumonia
51. Sulacillin in the treatment of bronchopulmonary diseases
52. Acute infectious exacerbations in chronic obstructive lung disease and effects of azithromycine, sultamycilline, ciprofloxacin and cefaclor monohydrate
53. Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor
54. Ampicillin/sulbactam in lower respiratory tract infections: a review
55. Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination
56. Amoxicillin/clavulanate-associated hepatic failure with progression to Stevens-Johnson syndrome
57. Community-acquired pneumonia: a North American perspective
58. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report
59. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association
60. Guidelines for the management of community-acquired pneumonia in adults. Italian Society of Pneumology/Italian Society of Respiratory Medicine Italian Society of Chemotherapy
61. Diagnostico y tratamiento de la neumonia adquirida en la communidad
62. Community-acquired pneumonia in adults: guidelines for management
63. Management of adult community-acquired lower respiratory tract infections
64. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease